司美格鲁肽对肥胖相关心衰患者心脏结构与功能的影响
STEP-HFpEF项目超声心动图亚组纳入491例肥胖相关HFpEF患者,随机接受每周一次司美格鲁肽2.4 mg或安慰剂治疗52周。司美格鲁肽减轻左房重构和右室扩大,并改善部分舒张功能指标,但未显著影响左室尺寸、质量或收缩功能。
要点
- 司美格鲁肽减轻肥胖相关HFpEF患者左房容积进展和右室扩大。
- 司美格鲁肽改善E波速度、E/A比值及E/e'平均值等舒张功能指标。
- 司美格鲁肽未显著影响左室尺寸、质量或收缩功能。
核心结论
- 在肥胖相关HFpEF患者中,司美格鲁肽2.4 mg每周一次治疗52周可改善不良心脏重构。
研究设计与样本
- STEP-HFpEF项目超声心动图亚组,纳入491/1145例(43%)肥胖相关HFpEF患者,随机接受司美格鲁肽2.4 mg每周一次(n=253)或安慰剂(n=238),基线和52周行超声心动图。
主要发现
- 司美格鲁肽减轻左房容积进展(估计平均差-6.13 mL;95%CI:-9.85至-2.41 mL;P=0.0013)。
- 司美格鲁肽减轻右室舒张末期面积增加(估计平均差-1.99 cm2;95%CI:-3.60至-0.38 cm2;P=0.016)和收缩末期面积增加(估计平均差-1.41 cm2;95%CI:-2.42至-0.40 cm2;P=0.0064)。
- 司美格鲁肽改善E波速度(估计平均差-5.63 cm/s;95%CI:-9.42至-1.84 cm/s;P=0.0037)、E/A比值(估计平均差-0.14;95%CI:-0.24至-0.04;P=0.0075)和E/e'平均值(估计平均差-0.79;95%CI:-1.60至0.01;P=0.05)。
- 上述关联不受糖尿病或房颤状态影响;司美格鲁肽未显著影响左室尺寸、质量或收缩功能。
- 司美格鲁肽减重越多与左房容积减少越多相关(Pinteraction=0.033),但与E波速度、E/e'平均值或右室舒张末期面积变化无关。
关键数值与推荐
- 预设主要结局为左房容积变化,其他超声参数变化作为次要结局。
- 采用协方差分析,按试验和体重指数分层,并校正基线参数值。
临床怎么用
- 对于肥胖相关HFpEF患者,司美格鲁肽2.4 mg每周一次可能作为改善心脏重构的疾病修饰治疗选择。
局限性
- 超声心动图亚组仅纳入STEP-HFpEF项目中43%的参与者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obesity is associated with adverse cardiac remodeling and is a key driver for the development and progression of heart failure (HF). Once-weekly semaglutide (2.4 mg) has been shown to improve HF-related symptoms and physical limitations, body weight, and exercise function in patients with obesity-related heart failure with preserved ejection fraction (HFpEF), but the effects of semaglutide on cardiac structure and function in this population remain unknown. OBJECTIVES: In this echocardiography substudy of the STEP-HFpEF Program, we evaluated treatment effects of once-weekly semaglutide (2.4 mg) vs placebo on cardiac structure and function. METHODS: Echocardiography at randomization and 52 weeks was performed in 491 of 1,145 participants (43%) in the STEP-HFpEF Program (pooled STEP-HFpEF [Semaglutide Treatment Effect in People with Obesity and HFpEF] and STEP-HFpEF DM [Semaglutide Treatment Effect in People with Obesity, HFpEF, and Type 2 Diabetes] trials). The prespecified primary outcome was change in left atrial (LA) volume, with changes in other echocardiography parameters evaluated as secondary outcomes. Treatment effects of semaglutide vs placebo were assessed using analysis of covariance stratified by trial and body mass index, with adjustment for baseline parameter values. RESULTS: Overall, baseline clinical and echocardiographic characteristics were balanced among those receiving semaglutide (n = 253) and placebo (n = 238). Between baseline and 52 weeks, semaglutide attenuated progression of LA remodeling (estimated mean difference [EMD] in LA volume, -6.13 mL; 95% CI: -9.85 to -2.41 mL; P = 0.0013) and right ventricular (RV) enlargement (EMD in RV end-diastolic area: -1.99 cm2; 95% CI: -3.60 to -0.38 cm2; P = 0.016; EMD in RV end-systolic area: -1.41 cm2; 95% CI: -2.42 to -0.40] cm2; P = 0.0064) compared with placebo. Semaglutide additionally improved E-wave velocity (EMD: -5.63 cm/s; 95% CI: -9.42 to -1.84 cm/s; P = 0.0037), E/A (early/late mitral inflow velocity) ratio (EMD: -0.14; 95% CI: -0.24 to -0.04; P = 0.0075), and E/e' (early mitral inflow velocity/early diastolic mitral annular velocity) average (EMD: -0.79; 95% CI: -1.60 to 0.01; P = 0.05). These associations were not modified by diabetes or atrial fibrillation status. Semaglutide did not significantly affect left ventricular dimensions, mass, or systolic function. Greater weight loss with semaglutide was associated with greater reduction in LA volume (Pinteraction = 0.033) but not with changes in E-wave velocity, E/e' average, or RV end-diastolic area. CONCLUSIONS: In the STEP-HFpEF Program echocardiography substudy, semaglutide appeared to improve adverse cardiac remodeling compared with placebo, further suggesting that treatment with semaglutide may be disease modifying among patients with obesity-related HFpEF. (Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity [STEP-HFpEF]; NCT04788511; Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes [STEP-HFpEF DM]; NCT04916470).
引用
- Solomon, Ostrominski, Wang, et al. Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure. J Am Coll Cardiol. 2024. PMID: 39217567. doi:10.1016/j.jacc.2024.08.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。